NCT05054413 Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
| NCT ID | NCT05054413 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Hematopoietic and Lymphoid Cell Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2021-04-15 |
| Primary Completion | 2030-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2021-04-15 with a primary completion date of 2030-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust Delphi technique, completely remote and electronic. The goal of this survey study is to have a panel of specialty-specific experts create a consensus agreement on a minimum set of key data elements for use in standardized reports. These recommendations would be used to develop standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivorship.
Eligibility Criteria
Inclusion Criteria: * Age 21 and above * Board certification in Radiation Oncology, Radiation Physics, Urology, and/or Medical Oncology * Maintenance of an active practice that includes prostate cancer patients * English speaking Exclusion Criteria: * Medical providers that are not board certified in the professions and/or those who do not treat prostate cancer * Prisoners, children, and adults unable to consent to participation will also be excluded * No exclusions were made based on sex, age, racial/ethnic background, or pregnancy status
Contact & Investigator
Amy C Moreno
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT05054413 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Hematopoietic and Lymphoid Cell Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05054413 currently recruiting?
Yes, NCT05054413 is actively recruiting participants. Contact the research team at akmoreno@mdanderson.org for enrollment information.
Where is the NCT05054413 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05054413 clinical trial?
NCT05054413 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Amy C Moreno at M.D. Anderson Cancer Center. The trial plans to enroll 10 participants.